고지방식이 유도 비알콜성지방간 마우스 모델에서 육신국(六神麯)의 지방간(脂肪肝) 개선효과

Abstract

ABSTRACT Objectives : This study was undertaken to verify the effects of Massa Medic ata Fermentata (MMF) on nonalcoholic fatty liver disease (NAFLD) using high fat diet-fed male mice.Methods : Fifty four male C57BL/6N mice (age matched) were used for all experiments. Nine standard chow diet-fed mice were used as normal group and forty five high fat diet-fed obese mice were randomly divided into 5 groups: control, atorvastatin-10㎎/㎏, MMF(1)-62.5㎎/㎏, MMF (2)-125㎎/㎏ and MMF(3)-250㎎/㎏. After all groups were treated with several kinds of diets for 8 weeks, we measured body weight gain, adipose tissue weights, plasma lipid and glucose metabolism, visceral organ we ights, histological analysis for liver on the mice.Results : MMF-treated mice had lower body weight gain compared with cont rols. Among MMF-treated mice, the effect was magnified in MMF(2). MMF(3)-treated mice had low er blood plasma total cholesterol (TC) and glucose level compared with controls. MMF decreased hepatic lip id accumulation, liver fibrosis and liver inflammation of mice compared with controls. The effects was maximized in MMF(2) and atorvastatin. Blood plasma aspartate aminotransferase (AST), alanine aminotransfera se (ALT), γ-glutamyltransferase (γ-GT) concentrations tends to be decreased by MMF compared with contr ols. Blood plasma AST, ALT, γ-GT concentrations and organ weights were not changed by MMF, indic ating that all three kinds of MMF do not show any hepatotoxicity.Conclusions : These results suggest that MMF improves NAFLD by reducing body weight gain, hepatic lipid accumulation, liver fibrosis, liver inflammation.Key words : Massa Medicata Fermentata, NAFLD, liver fibrosis, total cholesterol